Results 181 to 190 of about 6,539 (200)

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

Lancet Respiratory Medicine,the, 2014
Mario Castro, Eugene R Bleecker, Emilio Pizzichini   +2 more
exaly  

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Lancet Respiratory Medicine,the, 2018
J Mark Fitzgerald, Eugene R Bleecker, Andrew Menzies-Gow   +2 more
exaly  

Benralizumab/ciclosporin

Reactions Weekly, 2021
openaire   +1 more source

Benralizumab/Mepolizumab

Reactions Weekly
  +5 more sources

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Lancet Respiratory Medicine,the, 2019
Eugene R Bleecker, Ubaldo J Martin, Jorge F Maspero   +2 more
exaly  

Glucocorticoid Sparing of Benralizumab in Asthma

New England Journal of Medicine, 2017
Parameswaran Nair
exaly  

Benralizumab/mepolizumab/omalizumab

Reactions Weekly, 2021
openaire   +1 more source

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

Expert Opinion on Biological Therapy, 2012
William J Calhoun
exaly  

Benralizumab

Reactions Weekly, 2019
openaire   +1 more source

Benralizumab/mepolizumab/prednisolone

Reactions Weekly, 2023
openaire   +1 more source